SNP for predicting the sensitivity to anticancer targeted therapeutic formulation

A targeted therapy and sensitivity technology, applied in testing pharmaceutical preparations, testing organic pollutants in water, testing water, etc., can solve problems such as unsatisfactory research results and difficulty in securing a large number of samples

Inactive Publication Date: 2013-03-27
THE ASAN FOUND +1
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, due to the complex effect of factors related to the biological response to specific drugs, the diversity of therapeutic drugs and administration methods, and the difficulty of securing a large number of samples, satisfactory research results have not been obtained so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • SNP for predicting the sensitivity to anticancer targeted therapeutic formulation
  • SNP for predicting the sensitivity to anticancer targeted therapeutic formulation
  • SNP for predicting the sensitivity to anticancer targeted therapeutic formulation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0086] Example 1: The first stage of screening SNP genes

[0087] 118 patients with colorectal cancer were analyzed by highly aggregated high-speed SNP (using Affymetrix SNP Array 6.0) and in vitro tumor reactivity analysis, and the correlation analysis of these two results obtained 4163 SNPs with a -Log(p) value of 3 or more, from which Screen out 56 cross-inconsistency rates (R 2 ) 0.8 or more SNPs, thereby obtaining the basic information of the sensitive SNP genes of anti-cancer targeted therapy agents.

Embodiment 2

[0088] Example 2: The second stage of screening SNP genes

[0089] Among the SNP genes screened in the first stage above, the candidate SNPs with a frequency of more than 10% in the existing Japanese and Chinese analysis data (www.hanpmap.org) and linkage disequilibrium (Linkage disequilibrium) were screened Genes were additionally screened through non-synonymous, haplotype-tagging and functional SNPs to discover 15 candidate SNPs ( figure 1 ).

[0090] Then, 480 normal population lymphocyte DNA samples were used to identify the same SNP gene. In the identification results, 11 SNPs that were not significantly (p>0.01) out of the Hardy-Weinberg equilibrium were screened out as Candidate SNPs identified in the clinical association analysis performed for final characterization in Example 3 below (Table 1).

[0091] Table 1. Eleven candidate anticancer agent responsive candidate SNP markers among the eleven genes excavated through two stages of identification

[0092]

[009...

Embodiment 3

[0094] Example 3: Phases of association analysis between SNP genes and existing clinical processes

[0095] Clinically, 69 cases of bevacizumab use group and 67 cases of cetuximab use group were used as the research objects, and the clinical correlation analysis was carried out. The patient's clinical treatment process was tracked through the NCCN surveillance guideline (NCCN surveillance guideline) ( www.nccn.org ) was measured, and the tumor reactivity of anticancer agents was determined using RECIST criteria (Therasse et al., J Natl Cancer Inst 2000:92:205-16). The average follow-up observation period of patients is 13 months (range: 1-39 months). Since all the subjects of this preparation are patients with metastatic or recurrent cancer, the follow-up observation period of 13 months should be sufficient for judging the results time.

[0096] 3.1 Survival-related clinical correlations based on the anticancer targeted therapy preparation group analyze

[0097] Corr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a single nucleotide polymorphism (SNP) for predicting the sensitivity to an anticancer targeted therapeutic formulation, a polynucleotide containing the same, and a method for predicting the sensitivity to an anticancer targeted therapeutic formulation. According to the present invention, it is possible to predict the sensitivity of each individual to a certain anticancer targeted therapeutic formulation, using a small amount of a sample taken from a patient and thus to select a most suitable targeted therapeutic formulation over the entire duration of treatment for the patient.

Description

technical field [0001] The present invention relates to a single base polymorphism marker (SNP:Single Nucleotide Polymorphism) for predicting the sensitivity to anti-cancer targeted therapy agents, polynucleotides including the SNP and the ability to predict sensitivity to specific anti-cancer agents A method for the sensitivity of cancer-targeted therapeutic agents. Background technique [0002] Human individual genetic differences are mostly due to single base polymorphisms (SNPs), which in some genotypes appear as functional differences between corresponding proteins and their metabolism, and these differences are sensitive to human pharmacological genes Sex is closely related (Huang and Ratain, CA Cancer J Clin 2009, 59:42-55). [0003] On the one hand, many anticancer agents have good therapeutic effects clinically, but the resistance (resisitanccce) of cancer cells to anticancer agents is a new problem (Tsuruo et al., 1984). The resistance to anticancer agents is mai...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/11C12Q1/68G01N33/15
CPCC12Q2600/156C12Q1/68G01N33/18C12Q1/6886C12Q2600/106G01N33/1826G01N33/15C12N15/11
Inventor 金镇千金溶声金善荣赵桐衡
Owner THE ASAN FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap